CADL实时信号 | 通过Getagraph.com最大化利润

购买 2804 min ago

@ $11.45

发出时间: 17 May 2024 @ 23:14

回报率: 0.42%

上一信号: May 17 - 21:30

上一信号: 出售

回报率: -12.98 %

Live Chart Being Loaded With Signals

Commentary (18 May 2024 @ 04:00):

Stats
今日成交量	833 352
平均成交量	5.49M
市值	342.06M
EPS	$0 ( 2024-05-09 )
下一个收益日期	( $0 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.78
ATR14	$2.10 (18.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-12	Schoch Charles	Sell	0	Common Stock
2024-01-12	Schoch Charles	Sell	0	Common Stock
2024-01-12	Schoch Charles	Sell	25 000	Stock Option (Right to Buy)
2024-01-12	Schoch Charles	Sell	39 498	Stock Option (Right to Buy)
2023-11-28	Tyagarajan Seshu	Sell	17 328	Common Stock

INSIDER POWER
76.86
Last 92 transactions
Buy: 8 106 969 \| Sell: 4 393 086

音量相关性

長: -0.58 (weak negative)

短: 0.74 (moderate)

Signal:(50) Neutral

Candel Therapeutics, Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Candel Therapeutics, Inc. 相关性 - 货币/商品

-0.32
( neutral )

-0.47
( neutral )

0.00
( neutral )

-0.66
( moderate negative )

0.13
( neutral )

0.71
( moderate )

Candel Therapeutics, Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$-1.20M (0.00 %)
EPS:	$-1.310

FY	2023
营收:	$0
毛利润:	$-1.20M (0.00 %)
EPS:	$-1.310

FY	2022
营收:	$125 000
毛利润:	$-862 000 (-689.60 %)
EPS:	$-0.0994

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.934

Financial Reports:

No articles found.

Candel Therapeutics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.